Table 3.
Stock-out status of ARVs within 6 months prior to the study and percentage difference between ordered and received quantities of ARVs in health centers and hospitals, Addis Ababa, 2013
| ARV drugs | Stock-out days of ARVs within 6 months prior to the study | Percentage difference between ordered and received quantities of ARVS | ||||
|---|---|---|---|---|---|---|
| Health centers | Hospitals | Health centers | Hospitals | |||
| Average number of days ± SD | Average number of days ± SD | Mean percentage difference ± SD | (Min, Max) | Mean percentage difference ± SD | (min, max) | |
| EFV50 | 12 ± 21 | 0 | 0 | 0 | a | a |
| EFV200 | 10.1 ± 28 | 0 | 9.5 ± 21.2 | (0, 47.6) | 0 | 0 |
| EFV600 | 18.8 ± 25 | 0 | 47 ± 32.3 | (0, 80.7) | 2.9 ± 2.7 | (0, 11.5) |
| 3TC300/TDF300 | 45.9 ± 45.5 | 42.5 ± 60.1 | 51.7 ± 33.8 | (0, 99) | 69.6 ± 17 | (55, 93.4) |
| NVP 200 | 16.6 ± 30.8 | 36.5 ± 19.1 | 0 | 0 | 0 | 0 |
| ZDV300/3TC150 | 9.7 ± 13.9 | 34.5 ± 14.8 | 27.1 ± 43.1 | (0, 143) | 34 ± 29.5 | (0, 52) |
| ZDV300/3TC150/NVP200 | 13 ± 19.9 | 20.5 ± 4.9 | 14.8 ± 33.6 | (0, 93.6) | 50 ± 0 | (50,50) |
| 3TC30/ZDV60/NVP50 | 15 ± 17 | 0 | 0 | 0 | 0 | 0 |
| NVP 240 ml | 33.7 ± 46.7 | 29 ± 41 | 5.9 ± 16.6 | (0, 47.1) | 0 | 0 |
| D4T12/3TC60/NVP100 | 20.1 ± 25 | 27 ± 0.0 | 27.8 ± 83.5 | (0, 290) | 0 | 0 |
| D4T6/3TC30/NVP50 | 16.8 ± 24.4 | 0 | 110.8 ± 193.8 | (0, 400) | 0 | 0 |
| 3TC30/ZDV60 | 14.8 ± 21.8 | 16.5 ± 14.8 | 25.4 ± 35.9 | (0, 50.8) | 45.7 ± 12.7 | (36.7,54.7) |
| D4T 12/3TC60 | 15.6 ± 33.1 | 0 | 0 | 0 | 69.4 ± 33.3 | (45.8,93) |
| D4T 6/3TC30 | 55.8 ± 45 | 0 | a | a | 0 | 0 |
ameans the product was not ordered by the health facility in last requisition and reporting reviewed
D4T = Stavudine; EFV = Efavernez; NVP = Nevirapine; TDF = Tenofovir; 3TC = Lamivudine; ZDV = Zidovudine